Tracleer bosentan: Interim Phase IV data

Interim data from the open-label, U.S. and EU Phase IV COMPASS-1 trial in 45 patients receiving long-term Tracleer therapy showed that pulmonary vascular resistance decreased by 15% at 60 minutes afte...